---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-021482"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2025-06-30T23:59:59+00:00"
generated_at: "2026-05-18T14:43:44.384756+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Allarity dosed second patient in new Phase 2 stenoparib trial for advanced ovarian cancer

## Summary
- Second patient dosed in new Phase 2 trial of stenoparib for advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer.
- CEO Thomas Jensen cited strong investigator engagement and rapid enrollment pace.
- Trial builds on prior Phase 2 data showing durable benefit and favorable tolerability with twice-daily dosing.
- Stenoparib is a dual PARP and WNT pathway inhibitor; trial also advances DRP companion diagnostic.
- Current platinum-resistant patients have limited treatment options; stenoparib aims to offer a better-tolerated alternative.

## SEC filing metadata
- accession: 0001437749-25-021482
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2025-06-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000143774925021482/0001437749-25-021482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000143774925021482/allr20250630_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-021482
- JSON: https://secwatch.observer/filing/0001437749-25-021482.json
- Plain text: https://secwatch.observer/filing/0001437749-25-021482.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.